Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BridgeBio Pharma, Inc. (BBIO : NSDQ)

• Company Description    BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States. Number of Employees: 730

• Price / Volume Information    Yesterday's Closing Price: $61.80 Daily Weekly Monthly 20 Day Moving Average: 2,738,977 shares Shares Outstanding: 192.71 (millions) Market Capitalization: $11,909.40 (millions) Beta: 1.39 52 Week High: $69.48 52 Week Low: $21.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.37% 8.45% 12 Week 20.42% 15.43% Year To Date 125.22% 96.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3160 PORTER DR. SUITE 250 - PALO ALTO,CA 94304 USA ph: 650-391-9740 fax: - None http://www.bridgebio.com

• General Corporate Information    Officers Neil Kumar - Chief Executive Officer; Director Thomas Trimarchi - President; Chief Operating Officer Maricel M. Apuli - Chief Accounting Officer Eric Aguiar - Director Jennifer E. Cook - Director Peer Information BridgeBio Pharma, Inc. (BGMR) BridgeBio Pharma, Inc. (BBIO) BridgeBio Pharma, Inc. (IPAH) BridgeBio Pharma, Inc. (BRL) BridgeBio Pharma, Inc. (BHC) BridgeBio Pharma, Inc. (AKRXQ) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-GENERIC DRG Sector: Medical CUSIP: 10806X102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/19/26 Share - Related Items Shares Outstanding: 192.71 Most Recent Split Date: (:1) Beta: 1.39 Market Capitalization: $11,909.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.47 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 41.04% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 33.66 EPS Growth vs. Year Ago Period: -10.47% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 4,318.01% vs. Previous Quarter: 9.17% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - -80.47 06/30/25 - -85.69 03/31/25 - -94.43 Current Ratio 09/30/25 - 3.88 06/30/25 - 5.19 03/31/25 - 4.57 Quick Ratio 09/30/25 - 3.76 06/30/25 - 5.08 03/31/25 - 4.54 Operating Margin 09/30/25 - -220.60 06/30/25 - -322.17 03/31/25 - -604.04 Net Margin 09/30/25 - -225.32 06/30/25 - -329.25 03/31/25 - -524.25 Pre-Tax Margin 09/30/25 - -227.26 06/30/25 - -331.52 03/31/25 - -530.27 Book Value 09/30/25 - -9.98 06/30/25 - -9.30 03/31/25 - -8.63 Inventory Turnover 09/30/25 - 1.28 06/30/25 - 1.61 03/31/25 - 5.99 Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©